JP2015535816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535816A5 JP2015535816A5 JP2015532065A JP2015532065A JP2015535816A5 JP 2015535816 A5 JP2015535816 A5 JP 2015535816A5 JP 2015532065 A JP2015532065 A JP 2015532065A JP 2015532065 A JP2015532065 A JP 2015532065A JP 2015535816 A5 JP2015535816 A5 JP 2015535816A5
- Authority
- JP
- Japan
- Prior art keywords
- ala
- ile
- leu
- val
- met
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 108091008874 T cell receptors Proteins 0.000 claims 15
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000002437 synoviocyte Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261701056P | 2012-09-14 | 2012-09-14 | |
| US61/701,056 | 2012-09-14 | ||
| PCT/US2013/059608 WO2014043441A1 (en) | 2012-09-14 | 2013-09-13 | T cell receptors recognizing mhc class ii-restricted mage-a3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243703A Division JP6728326B2 (ja) | 2012-09-14 | 2018-12-26 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535816A JP2015535816A (ja) | 2015-12-17 |
| JP2015535816A5 true JP2015535816A5 (cg-RX-API-DMAC7.html) | 2016-11-04 |
| JP6461796B2 JP6461796B2 (ja) | 2019-01-30 |
Family
ID=49253425
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532065A Active JP6461796B2 (ja) | 2012-09-14 | 2013-09-13 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2018243703A Active JP6728326B2 (ja) | 2012-09-14 | 2018-12-26 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2020114090A Active JP6923714B2 (ja) | 2012-09-14 | 2020-07-01 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2021124003A Active JP7270001B2 (ja) | 2012-09-14 | 2021-07-29 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243703A Active JP6728326B2 (ja) | 2012-09-14 | 2018-12-26 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2020114090A Active JP6923714B2 (ja) | 2012-09-14 | 2020-07-01 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 |
| JP2021124003A Active JP7270001B2 (ja) | 2012-09-14 | 2021-07-29 | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9879065B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2895509B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6461796B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR102165350B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104968675B (cg-RX-API-DMAC7.html) |
| AU (4) | AU2013315391B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2884743C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1122720T1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK2895509T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2774931T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20200325T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE048014T2 (cg-RX-API-DMAC7.html) |
| IL (3) | IL286786B (cg-RX-API-DMAC7.html) |
| LT (1) | LT2895509T (cg-RX-API-DMAC7.html) |
| MX (2) | MX367279B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2895509T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2895509T (cg-RX-API-DMAC7.html) |
| SI (1) | SI2895509T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202000103T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014043441A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9879065B2 (en) * | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
| ES2776698T3 (es) | 2012-12-20 | 2020-07-31 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| CN119409799A (zh) * | 2014-10-02 | 2025-02-11 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法 |
| CA2963364A1 (en) | 2014-10-02 | 2016-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells having antigenic specificity for a cancer-specific mutation |
| ES2952959T3 (es) * | 2015-03-27 | 2023-11-07 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra diversos tumores (SEQ ID N.º 25 - MXRA5-003) |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| WO2017070042A1 (en) | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using akt inhibitors |
| WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
| EP3416668A4 (en) | 2016-02-18 | 2020-02-19 | The Wistar Institute Of Anatomy And Biology | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA |
| GB201604494D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| HUE060725T2 (hu) | 2016-03-16 | 2023-04-28 | Immatics Biotechnologies Gmbh | Transzfektált T-sejtek és T-sejt receptorok daganatok ellen alkalmazott immunterápiában történõ használatra |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| CN106749620B (zh) * | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| WO2018097951A1 (en) | 2016-11-22 | 2018-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3/a6 antibodies |
| DE102016123859B3 (de) | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| CN108250289B (zh) * | 2016-12-28 | 2021-10-08 | 香雪生命科学技术（广东）有限公司 | 源自于mage b6的肿瘤抗原短肽 |
| CN110121336A (zh) | 2017-01-05 | 2019-08-13 | 弗莱德哈钦森癌症研究中心 | 改善疫苗功效的系统和方法 |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| CA3077595A1 (en) * | 2017-10-05 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
| WO2019075055A1 (en) | 2017-10-11 | 2019-04-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS |
| CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
| CN109836490A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向mage-a3的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用 |
| CN109837248A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种tcr敲除的靶向mage-a3的t细胞受体基因修饰t细胞及其制备方法和应用 |
| CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | Car t细胞的使用方法 |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN118374524A (zh) | 2018-02-09 | 2024-07-23 | 美国卫生和人力服务部 | 拴系白细胞介素-15和白细胞介素-21 |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| WO2019204683A1 (en) * | 2018-04-19 | 2019-10-24 | Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
| US12415845B2 (en) | 2018-04-24 | 2025-09-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| CA3146845A1 (en) * | 2019-07-15 | 2021-01-21 | Neogene Therapeutics B.V. | Method to isolate tcr genes |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| JP2020143057A (ja) * | 2020-04-01 | 2020-09-10 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
| US20230258635A1 (en) | 2020-09-08 | 2023-08-17 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | T cell phenotypes associated with response to adoptive cell therapy |
| EP4243937A2 (en) | 2020-11-13 | 2023-09-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| EP4456911A2 (en) | 2021-12-31 | 2024-11-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell therapy with vaccination as a combination immunotherapy against cancer |
| CN117946247B (zh) * | 2023-02-23 | 2024-08-09 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025160480A1 (en) | 2024-01-26 | 2025-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1 |
| WO2025250587A1 (en) | 2024-05-29 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug-regulatable, inducible cytokine expression |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IN165717B (cg-RX-API-DMAC7.html) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| WO2012013913A1 (en) | 2010-07-28 | 2012-02-02 | Immunocore Ltd | T cell receptors |
| CA3071740C (en) * | 2010-09-20 | 2020-09-08 | Biontech Ag | Antigen-specific t cell receptors and t cell epitopes |
| WO2012054825A1 (en) | 2010-10-22 | 2012-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3 t cell receptors and related materials and methods of use |
| CN102251033B (zh) * | 2011-07-05 | 2013-03-20 | 北京大学人民医院 | 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒 |
| EP3766896B1 (en) | 2011-09-15 | 2025-11-05 | The United States of America, as represented by The Secretary, Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| US9413985B2 (en) * | 2012-09-12 | 2016-08-09 | Lattice Semiconductor Corporation | Combining video and audio streams utilizing pixel repetition bandwidth |
| US9879065B2 (en) * | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
-
2013
- 2013-09-13 US US14/427,671 patent/US9879065B2/en active Active
- 2013-09-13 WO PCT/US2013/059608 patent/WO2014043441A1/en not_active Ceased
- 2013-09-13 HU HUE13767200A patent/HUE048014T2/hu unknown
- 2013-09-13 AU AU2013315391A patent/AU2013315391B2/en active Active
- 2013-09-13 DK DK13767200.2T patent/DK2895509T3/da active
- 2013-09-13 MX MX2015003061A patent/MX367279B/es active IP Right Grant
- 2013-09-13 DK DK19212016.0T patent/DK3636665T3/da active
- 2013-09-13 KR KR1020157006543A patent/KR102165350B1/ko active Active
- 2013-09-13 CN CN201380059102.4A patent/CN104968675B/zh active Active
- 2013-09-13 KR KR1020207028713A patent/KR102303166B1/ko active Active
- 2013-09-13 SI SI201331678T patent/SI2895509T1/sl unknown
- 2013-09-13 CA CA2884743A patent/CA2884743C/en active Active
- 2013-09-13 PT PT137672002T patent/PT2895509T/pt unknown
- 2013-09-13 PL PL13767200T patent/PL2895509T3/pl unknown
- 2013-09-13 LT LTEP13767200.2T patent/LT2895509T/lt unknown
- 2013-09-13 EP EP13767200.2A patent/EP2895509B1/en active Active
- 2013-09-13 HR HRP20200325TT patent/HRP20200325T1/hr unknown
- 2013-09-13 ES ES13767200T patent/ES2774931T3/es active Active
- 2013-09-13 EP EP19212016.0A patent/EP3636665B1/en active Active
- 2013-09-13 SM SM20200103T patent/SMT202000103T1/it unknown
- 2013-09-13 CN CN202111028896.0A patent/CN113754755A/zh active Pending
- 2013-09-13 ES ES19212016T patent/ES2925307T3/es active Active
- 2013-09-13 EP EP22174521.9A patent/EP4159753A1/en active Pending
- 2013-09-13 KR KR1020227006700A patent/KR102480188B1/ko active Active
- 2013-09-13 IL IL286786A patent/IL286786B/en unknown
- 2013-09-13 KR KR1020217029207A patent/KR102370307B1/ko active Active
- 2013-09-13 JP JP2015532065A patent/JP6461796B2/ja active Active
-
2015
- 2015-03-04 IL IL237560A patent/IL237560B/en active IP Right Grant
- 2015-03-10 MX MX2019009641A patent/MX2019009641A/es unknown
-
2017
- 2017-08-23 AU AU2017219019A patent/AU2017219019B2/en active Active
- 2017-12-20 US US15/848,344 patent/US10611815B2/en active Active
-
2018
- 2018-12-26 JP JP2018243703A patent/JP6728326B2/ja active Active
-
2019
- 2019-08-06 AU AU2019213329A patent/AU2019213329B2/en active Active
-
2020
- 2020-03-03 CY CY20201100190T patent/CY1122720T1/el unknown
- 2020-03-09 US US16/812,845 patent/US20200270329A1/en not_active Abandoned
- 2020-04-16 IL IL274003A patent/IL274003B/en unknown
- 2020-07-01 JP JP2020114090A patent/JP6923714B2/ja active Active
-
2021
- 2021-06-07 AU AU2021203746A patent/AU2021203746B2/en active Active
- 2021-07-29 JP JP2021124003A patent/JP7270001B2/ja active Active
-
2022
- 2022-09-28 US US17/936,006 patent/US12404317B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535816A5 (cg-RX-API-DMAC7.html) | ||
| HRP20200325T1 (hr) | T-stanični receptori koji prepoznaju mhc razred ii-ograničenog mage-a3 | |
| CN112300269B (zh) | Kras突变特异性t细胞受体筛选及抗肿瘤用途 | |
| JP2015525208A5 (cg-RX-API-DMAC7.html) | ||
| TWI880898B (zh) | 單鏈嵌合多肽及其用途 | |
| JP2018535647A5 (cg-RX-API-DMAC7.html) | ||
| CN113784986B (zh) | 间皮素特异性嵌合抗原受体及表达它的t细胞 | |
| US20170267738A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| CA2848209C (en) | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage | |
| EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
| FI3688027T3 (fi) | Mutatoidun p53:n tunnistavia t-solureseptoreita | |
| IL301894B1 (en) | Anti-kras-g12d t cell receptors | |
| IL275497B (en) | Serum proteins with type iii fibronectin binding domains | |
| WO2020082130A1 (en) | T-cell receptors and uses thereof | |
| AU2018335274A1 (en) | HLA class II–restricted T cell receptors against mutated RAS | |
| JP2017536825A5 (cg-RX-API-DMAC7.html) | ||
| WO2008039818A3 (en) | Modified t cell receptors and related materials and methods | |
| WO2009042570A3 (en) | Modified t cell receptors and related materials and methods | |
| RU2016124670A (ru) | Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения | |
| Piatesi et al. | Directed evolution for improved secretion of cancer–testis antigen NY-ESO-1 from yeast | |
| CA2967778A1 (en) | Anti-thyroglobulin t cell receptors | |
| Zhang et al. | A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus | |
| CN108779164A (zh) | Hla-b57开放型构象异构体 | |
| CN101565455B (zh) | 禽流感h5n1病毒的ctl表位多肽及其应用 | |
| CN114853880A (zh) | Wt1抗原特异性t细胞受体及其抗肿瘤用途 |